Anti-BCL11A [BCL11A/123]

Cat. #151750

Anti-BCL11A [BCL11A/123]

Cat. #: 151750

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: BCL11A (EVI9, CTIP1)

Class: Monoclonal

Application: IHC ; IP ; WB

Reactivity: Human ; Rat

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Alison Banham

Institute: University of Oxford

Tool Details
Target Details

Tool Details


  • Name: Anti-BCL11A [BCL11A/123]
  • Clone: BCL11A/123
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: Predicted 91 kDa
  • Reactivity: Human ; Rat
  • Host: Mouse
  • Application: IHC ; IP ; WB
  • Description: The BCL11A/123 antibody specifically recognises the extra long form of the protein and not the long or short forms of BCL11A. The BCL11A/123 antibody is not cross reactive with the long form of the BCL11B protein that shares significant sequence identity with the immunogen.
  • Immunogen: C-terminus of extra long isoform of BCL11A, BCL11AXL (aa 637-835)
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1
  • Recommended controls: Tonsil (in B cells and plasmcytoid dendritic cells), Neurones and nuclei of some epithelium

Target Details

  • Target: BCL11A (EVI9, CTIP1)
  • Molecular weight: Predicted 91 kDa
  • Tissue cell line specificity: Tonsil (in B cells and plasmcytoid dendritic cells), Neurones and nuclei of some epithelium
  • Target background: BCL11A is a KrĂźppel zinc-finger transcription factor that was identified originally from a chromosome translocation in aggressive B-cell chronic lymphocytic leukaemia. The gene may function as both an oncogene and a tumour suppressor. Alternative splicing generates multiple isoforms, the BCL11AXL being the largest and most abundant transcript. The protein is differentially expressed during B-cell development and is strongly expressed in plasmacytoid dendritic cells.


  • Application: IHC ; IP ; WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C


  • Chetaille et al. 2009. Blood. 113(12):2765-3775. PMID: 19096012.
  • Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
  • Marafioti et al. 2008. Blood. 111(7):3778-92. PMID: 18218851.
  • Novel markers of normal and neoplastic human plasmacytoid dendritic cells.
  • Weniger et al. 2006. Leukemia. 20(10):1880-2. PMID: 16871282.
  • Pulford et al. 2006. Leukemia. 20(8):1439-41. PMID: 16710303.
  • Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.
  • The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells.
  • Liu et al. 2006. Mol Cancer. 5:18. PMID: 16704730.
  • Fn studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.